Exhibit 4.6
DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934
The following is a description of the authorized capital stock of Atossa Therapeutics, Inc. (the “Company” or “we” or “our”). The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation, as amended from time to time (the “Certificate of Incorporation”), and our Amended and Restated By-laws (the “By-laws”), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this exhibit is a part. We encourage you to read our Certificate of Incorporation, our By-laws and the applicable provisions of the Delaware General Corporation Law (the “DGCL”) for additional information.
As of the date of the Annual Report on Form 10-K of which this exhibit is a part, our authorized capital stock consisted of: (i) 350,000,000 shares of common stock, par value $0.18 per share (the “Common Stock”), and 10,000,000 shares of preferred stock, par value $0.001 per share (the “Preferred Stock”), of which 750,000 shares are designated as Series A junior participating preferred stock, par value $0.001 per share, 4,000 shares are designated as Series A convertible preferred stock, par value $0.001 per share, 25,000 shares are designated as Series B convertible preferred stock, par value $0.001 per share, and 20,000 shares are designated as Series C convertible preferred stock, par value $0.001 per share.
Description of Common Stock
Voting Rights. The holders of our Common Stock are entitled to one vote per share on all matters to be voted upon by the stockholders; provided, however, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to the Certificate of Incorporation that alters or changes the powers, preferences, rights or other terms of one or more outstanding series of Preferred Stock if the holders of such affected series of Preferred Stock are entitled to vote on such amendment. When a quorum is present at any meeting of our stockholders, the affirmative vote of a majority of the votes properly cast on the matter (excluding any abstentions or broker non-votes) will be the act of the stockholders with respect to all matters other than the election of directors (which will be elected by a plurality of all votes properly cast), or as otherwise provided in the By-laws, the Certificate of Incorporation or a preferred stock designation, or as otherwise required by law.
Dividends. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of our Common Stock are entitled to receive ratably all dividends, if any, as may be declared from time to time by our Board of Directors out of the funds legally available.
Other Rights. In the event of the liquidation, dissolution or winding up of the Company, the holders of our Common Stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of Preferred Stock, if any, then outstanding. The Common Stock has no preemptive or conversion rights. There are no redemption or sinking fund provisions applicable to the common stock. All outstanding shares of common stock are fully paid and non-assessable.
Transfer Agent and Registrar. The transfer agent and registrar for our common stock is VSTOCK Transfer, LLC.
Listing. Our common stock is currently listed on The Nasdaq Capital Market under the symbol “ATOS”.
Certain Provisions Affecting Control of the Company
Certificate of Incorporation and By-law Provisions. Some provisions of the DGCL and our Certificate of Incorporation and By-laws contain provisions that could make the following transactions more difficult: